Use of a fundamental approach to spray-drying formulation design to facilitate the development of multi-component dry powder aerosols for respiratory drug delivery

Pharmaceutical Research

Volumn 31, Issue 2, 2014, Pages 449-465

  Hoe, Susan ^a   Ivey, James W ^a   Boraey, Mohammed A ^a   Shamsaddini Shahrbabak, Abouzar ^a   Javaheri, Emadeddin ^a   Matinkhoo, Sadaf ^a   Finlay, Warren H ^a   Vehring, Reinhard ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

antimicrobial; D amino acids; in silico; lung; particle formation model; spray drying

Indexed keywords

DEXTRO AMINO ACID; LEUCINE; METHIONINE; TREHALOSE; TRYPTOPHAN; TYROSINE; AMINO ACID; EXCIPIENT;

AEROSOL; AIRFLOW; AIRWAY DYNAMICS; ARTICLE; COMPUTER SIMULATION; CONTROLLED STUDY; CRYSTALLIZATION; DISPERSION; DRUG FORMULATION; DRY POWDER INHALER; IN VITRO STUDY; LUNG CLEARANCE; PARTICLE SIZE; PRIORITY JOURNAL; SPRAY DRYING; CHEMISTRY; DRUG DELIVERY SYSTEM; LUNG; MEDICINAL CHEMISTRY; METABOLISM; METHODOLOGY; PHARMACEUTICS; POWDER;

AEROSOLS; AMINO ACIDS; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; DRY POWDER INHALERS; EXCIPIENTS; LUNG; POWDERS; TECHNOLOGY, PHARMACEUTICAL; TREHALOSE;

EID: 84896704931     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1174-5     Document Type: Article

References (53)

1. Weers JG, Bell J, Chan HK, Cipolla D, Dunbar C, Hickey AJ, et al. Pulmonary formulations: what remains to be done? J Aerosol Med Pulm Drug Deliv. 2010;23:S5-S23.
2. Vehring R, Foss WR, Lechuga-Ballesteros D. Particle formation in spray drying. J Aerosol Sci. 2007;38:728-46.
3. Nandiyanto ABD, Okuyama K. Progress in developing spray-drying methods for the production of controlled morphology particles: from the nanometer to submicrometer size ranges. Adv Powder Technol. 2011;22:1-19.
4. Dobry DE, Settell DM, Baumann JM, Ray RJ, Graham LJ, Beyerinck RA. A model-based methodology for spray-drying process development. J Pharm Innov. 2009;4:133-42.
5. Ivey JW, Vehring R. The use of modeling in spray drying of emulsions and suspensions accelerates formulation and process development. Comput Chem Eng. 2010;34:1036-40.
6. Boraey MA, Matinkhoo S, Vehring R. A new time and cost effective approach for the development of microparticles for pulmonary drug delivery. In: Dalby RN, Byron PR, Peart J, Suman JD, Young PM, editors. Respiratory drug delivery Europe, vol. 2. Davis Healthcare International Publishing: Berlin, Germany; 473. p. 478-2011.
7. Feng AL, Boraey MA, Gwin MA, Finlay PR, Kuehl PJ, Vehring R. Mechanistic models facilitate efficient development of leucine containing microparticles for pulmonary drug delivery. Int J Pharm. 2011;409:156-63.
8. McCaughey G, McKevitt M, Elborn JS, Tunney MM. Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions. J Cyst Fibros. 2012;11:163-72.
9. Cava F, Lam H, de Pedro MA, Waldor MK. Emerging knowledge of regulatory roles of d-amino acids in bacteria. Cell Mol Life Sci. 2011;68:817-31.
10. Stewart PS, Franklin MJ. Physiological heterogeneity in biofilms. Nat Rev Microbiol. 2008;6:199-210.
11. Ashish A, Shaw M, Winstanley C, Ledson MJ, Walshaw MJ. Increasing resistance of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF) - A cause for concern? J Cyst Fibros. 2012;11:173-9.
12. Perez LRR, Barth AL. Biofilm production using distinct media and antimicrobial susceptibility profile of Pseudomonas aeruginosa. Braz J Infect Dis. 2011;15:301-4.
13. Ren CL, Konstan MW, Yegin A, Rasouliyan L, Trzaskoma B, Morgan WJ, et al. Multiple antibiotic-resistant Pseudomonas aeruginosa and lung function decline in patients with cystic fibrosis. J Cyst Fibros. 2012;11:293-9.
14. Tingpej P, Elkins M, Rose B, Hu H, Moriarty C, Manos J, et al. Clinical profile of adult cystic fibrosis patients with frequent epidemic clones of Pseudomonas aeruginosa. Respirology. 2010;15:923-9.
15. Kolodkin-Gal I, Romero D, Cao S, Clardy J, Kolter R, Losick R. D-amino acids trigger biofilm disassembly. Science. 2010;328:627-9.
16. Sanchez Z, Tani A, Kimbara K. Extensive reduction of cell viability and enhanced matrix production in pseudomonas aeruginosa PAO1 flow biofilms treated with a D-amino acid mixture. Appl Environ Microbiol. 2013;79:1396-9.
17. Stewart PS. A review of experimental measurements of effective diffusive permeabilities and effective diffusion coefficients in biofilms. Biotechnol Bioeng. 1998;59:261-72.
18. Vehring R. Pharmaceutical particle engineering via spray drying. Pharm Res. 2008;25:999-1022.
19. Javaheri E, Shemirani FM, Pichelin M, Katz IM, Caillibotte G, Vehring R, et al. Deposition modeling of hygroscopic saline aerosols in the human respiratory tract: comparison between air and helium-oxygen as carrier gases. J Aerosol Sci. 2013. doi: 10.1016/j.jaerosci.2013.04.010.
20. Lange CF, Hancock REW, Samuel J, Finlay WH. In vitro aerosol delivery and regional airway surface liquid concentration of a liposomal cationic peptide. J Pharm Sci. 2001;90:1647-57.
21. Hasan MA, Lange CF. Estimating in vivo airway surface liquid concentration in trials of inhaled antibiotics. J Aerosol Med. 2007;20:282-93.
22. Weers JG, Tarara TE, Clark AR. Design of fine particles for pulmonary drug delivery. Expert Opin Drug Deliv. 2007;4:297-313.
23. Finlay WH, Stapleton KW, Zuberbuhler P. Fine particle fraction as a measure of mass depositing in the lung during inhalation of nearly isotonic nebulized aerosols. J Aerosol Sci. 1997;28:1301-9.
24. Stahlhofen W, Rudolf G, James AC. Intercomparison of experimental regional aerosol deposition data. J Aerosol Med. 1989;2:285-308.
25. Aquino RP, Prota L, Auriemma G, Santoro A, Mencherini T, Colombo G, et al. Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells. Int J Pharm. 2012;426:100-7.
26. Son YJ, Worth Longest P, Hindle M. Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: effect of spray drying process conditions on aerosol performance. Int J Pharm. 2013;443:137-45.
27. Sou T, Kaminskas LM, Nguyen T-H, Carlberg R, McIntosh MP, Morton DAV. The effect of amino acid excipients on morphology and solid-state properties of multi-component spray-dried formulations for pulmonary delivery of biomacromolecules. Eur J Pharm Biopharm. 2013;83:234-43.
28. Hoe S, Matinkhoo S, Boraey MA, Ivey JW, Shamsaddini-Shahrbabak A, Finlay WH, et al. Substitution of L-Leucine with D-Leucine in spray-dried respirable powders for control of Pseudomonas aeruginosa infection. Chapel Hill: International Society for Aerosols in Medicine (ISAM); 2013.
29. Matinkhoo S, Hoe S, Boraey MA, Shamsaddini-Shahrbabak A, Finlay WH, and Vehring R: Spray drying D-amino acids to develop respirable dry powder for the treatment of Pseudomonas aeruginosa biofilms. American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition: Chicago, IL, 2012.
30. Adi S, Adi H, Tang P, Traini D, Chan HK, Young PM. Micro-particle corrugation, adhesion and inhalation aerosol efficiency. Eur J Pharm Sci. 2008;35:12-8.
31. Weiler C, Egen M, Trunk M, Langguth P. Force control and powder dispersibility of spray dried particles for inhalation. J Pharm Sci. 2010;99:303-16.
32. Ogan Ó, Li J, Tajber L, Corrigan OI, Healy AM. Particle engineering of materials for oral inhalation by dry powder inhalers. I - Particles of sugar excipients (trehalose and raffinose) for protein delivery. Int J Pharm. 2011;405:23-35.
33. Shoyele SA, Cawthorne S. Particle engineering techniques for inhaled biopharmaceuticals. Adv Drug Deliv Rev. 2006;58:1009-29.
34. Hancock BC, Shamblin SL, Zografi G. Molecular mobility of amorphous pharmaceutical solids below their glass-transition temperatures. Pharm Res. 1995;12:799-806.
35. Zhou DL, Zhang GGZ, Law D, Grant DJW, Schmitt EA. Physical stability of amorphous pharmaceuticals: importance of configurational thermodynamic quantities and molecular mobility. J Pharm Sci. 2002;91:1863-72.
36. Dranca I, Bhattacharya S, Vyazovkin S, Suryanarayanan R. Implications of global and local mobility in amorphous sucrose and trehalose as determined by differential scanning calorimetry. Pharm Res. 2009;26:1064-72.
37. Ekdawi-Sever N, De Pablo JJ, Feick E, Von Meerwall E. Diffusion of sucrose and α, α-trehalose in aqueous solutions. J Phys Chem A. 2003;107:936-43.
38. Umecky T, Kuga T, Funazukuri T. Infinite dilution binary diffusion coefficients of several α-amino acids in water over a temperature range from (293.2 To 333.2) K with the taylor dispersion technique. J Chem Eng Data. 2006;51:1705-10.
39. Chan TL, Lippmann M. Experimental measurements and empirical modelling of the regional deposition of inhaled particles in humans. Am Ind Hyg Assoc J. 1980;41:399-409.
40. Heyder J. Gravitational deposition of aerosol particles within a system of randomly oriented tubes. J Aerosol Sci. 1975;6:133-7.
41. Heyder J, Gebhart J. Gravitational deposition of particles from laminar aerosol flow through inclined circular tubes. J Aerosol Sci. 1977;8:289-95.
42. Ingham DB. Diffusion of aerosols from a stream flowing through a cylindrical tube. J Aerosol Sci. 1975;6:125-32.
43. Vehring R. Red-excitation dispersive Raman spectroscopy is a suitable technique for solid-state analysis of respirable pharmaceutical powders. Appl Spectrosc. 2005;59:286-92.
44. Boraey MA, Hoe S, Sharif H, Miller DP, Lechuga-Ballesteros D, Vehirng R. Improvement of the dispersibility of spray-dried budesonide powders using leucine in an ethanol-water cosolvent system. Powder Technol. 2013;236:171-8.
45. Vehring R, Ivey JW, Williams L, Joshi V, Dwivedi S, and Lechuga-Ballesteros D: High-sensitivity analysis of crystallinity in respirable powders using low-frequency shift Raman spectrocopy. In: RN Dalby, PR Byron, J Peart, JD Suman, and PM Young, editors, Respiratory drug delivery Vol II. Davis Healthcare International Publishing; 2012. pp. 641-644.
46. Shamsaddini-Sharbabak A, Vehring R. The compression behavior of respirable powders at different relative humidity measured by a compressed bulk density tester for small sample masses. In: Dalby RN, Byron PR, Peart J, Suman JD, Young PM, editors. Respiratory drug delivery, vol. III. River Grove: Davis Healthcare International Publishing; 777. p. 780-2012.
47. Naini V, Byron PR, Phillips EM. Physicochemical stability of crystalline sugars and their spray-dried forms: dependence upon relative humidity and suitability for use in powder inhalers. Drug Dev Ind Pharm. 1998;24:895-909.
48. Raula J, Thielmann F, Naderi M, Lehto VP, Kauppinen EI. Investigations on particle surface characteristics vs. dispersion behaviour of l-leucine coated carrier-free inhalable powders. Int J Pharm. 2010;385:79-85.
49. Stapleton KW, Guentsch E, Hoskinson MK, Finlay WH. On the suitability of k-epsilon turbulence modelling for aerosol deposition in the mouth and throat:a comparison with experiment. J Aerosol Sci. 2000;31:739-49.
50. Chen XD, Sidhu H, Nelson M. Theoretical probing of the phenomenon of the formation of the outermost surface layer of a multi-component particle, and the surface chemical composition after the rapid removal of water in spray drying. Chem Eng Sci. 2011;66:6375-84.
51. Roe KD, Labuza TP. Glass transition and crystallization of amorphous trehalose-sucrose mixtures. Int J Food Prop. 2005;8:559-74.
52. Ding SP, Fan J, Green JL, Lu Q, Sanchez E, Angell CA. Vitrification of trehalose by water loss from its crystalline dihydrate. J Therm Anal. 1996;47:1391-405.
53. Clark AR, Hollingworth AM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers - Implications for in vitro testing. J Aerosol Med. 1993;6:99-110.